Get started
Author

Matthew W. Hruska

Observed names: M HRUSKA, M. Hruska, M. W. Hruska, Matt Hruska, Matthew Hruska, Matthew W Hruska
ORCID: 0009-0000-8260-6003
Observed ORCID: 0009-0000-8260-6003
OpenAlex ID: A5080799931
Effect of St John's wort on imatinib mesylate pharmacokinetics
2004 · R FRYE, S FITZGERALD, et al. · Clinical Pharmacology & Therapeutics · 263
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
2017 · X. Zhao, S. Suryawanshi, et al. · Annals of Oncology · 255
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects
2004 · M. W. Hruska, J. A. Amico, et al. · British Journal of Clinical Pharmacology · 61
PDF
Simplified method for determination of rosiglitazone in human plasma
2004 · Matthew W Hruska, Reginald F Frye · Journal of Chromatography B · 41
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects: The Journal of Clinical Pharmacology / Vol XX No X 2016
2016 · Li Zhu, Roger J. Brüggemann, et al. · The Journal of Clinical Pharmacology · 40
Anti-Peg Antibody Bioanalysis: A Clinical Case Study with Peg-Ifn-λ-1A and Peg-Ifn-α2A in Naive Patients
2015 · Heather Myler, Matthew W Hruska, et al. · Bioanalysis · 34
Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 Enzymes
2004 · Matthew W Hruska, Reginald F Frye, et al. · Clinical Chemistry · 31
Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
2015 · Li Zhu, Matthew Hruska, et al. · Antimicrobial Agents and Chemotherapy · 29
PDF
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
2019 · Mayu Osawa, Mayumi Hasegawa, et al. · Cancer Chemotherapy and Pharmacology · 23
PDF
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
2016 · Ishani Landry, Li Zhu, et al. · Antimicrobial Agents and Chemotherapy · 21
Population Pharmacokinetics and Exposure — Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
2018 · Xiaoli Wang, Elizabeth A. Ludwig, et al. · The Journal of Clinical Pharmacology · 19
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
2016 · Graham R. Foster, Kazuaki Chayama, et al. · SpringerPlus · 13
PDF
Determination of trimethoprim in low-volume human plasma by liquid chromatography
2004 · Matthew W Hruska, Reginald F Frye · Journal of Chromatography B · 11
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables
2014 · Matthew Hruska, Xiaodong Wang, et al. · The Journal of Clinical Pharmacology · 10
First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors
2025 · Timothy A. Yap, Olivier Rixe, et al. · Cancer · 7
PDF
Measuring Biotherapeutics with Endogenous Counterparts and Pre-Existing Antibodies: an Interferon Case Study
2014 · Heather Myler, Tonya Felix, et al. · Bioanalysis · 7
Effect of CYP2C8 genotype on rosiglitazone pharmacokinetics
2005 · M HRUSKA, J CHEONG, et al. · Clinical Pharmacology & Therapeutics · 7
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
2014 · Xiaodong Wang, Matthew Hruska, et al. · The Journal of Clinical Pharmacology · 6
Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia
2024 · Matthew W. Hruska, Lamia Sid‐Otmane, et al. · Clinical Pharmacology & Therapeutics · 4
PDF
Pharmacodynamic Exposure–Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH
2024 · Krina Mehta, Jose Storopoli, et al. · The Journal of Clinical Pharmacology · 4
PDF
Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors
2016 · X. Zhao, S. Suryawanshi, et al. · Annals of Oncology · 4
Item Response Theory Quantifies the Relationship Between Improvements in Serum Phosphate and Patient‐Reported Outcomes in Adults With X‐Linked Hypophosphatemia
2024 · Krina Mehta, Nathalie H. Gosselin, et al. · Clinical Pharmacology & Therapeutics · 3
PDF
Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW‐6356 Following Single and Multiple Oral Administration in Healthy Volunteers
2023 · Tomonori Tayama, Masatake Ishiuchi, et al. · Clinical Pharmacology in Drug Development · 3
PDF
The pharmacokinetics of peginterferon lambda‐1a following single dose administration to subjects with impaired renal function
2015 · Matthew W. Hruska, Robert Adamczyk, et al. · British Journal of Clinical Pharmacology · 3
PDF
Effect of St. John's Wort administration on CYP2C8 mediated rosiglitazone metabolism
2005 · M HRUSKA, J CHEONG, et al. · Clinical Pharmacology & Therapeutics · 3
Works count: 38
Citation count: 905
H-index: 12
I10-index: 14
Year
Topic
Type